



# MEN WITH METASTATIC PROSTATE CANCER AREN'T ALL THE SAME

## UNCOVER *BRCA* IN PROSTATE CANCER




Metastatic prostate cancer patients with **HRR** mutations such as ***BRCA1/2*** may face **MORE AGGRESSIVE DISEASE** and **POORER PROGNOSIS**<sup>1-4</sup>



It's crucial to **UNCOVER** these mutations upon metastatic diagnosis to help identify precision medicine options<sup>3-5</sup>

Men with ***BRCA2*** mutations may face shorter prostate cancer-specific survival than those without (N=419)<sup>6</sup>



# BIOMARKER TESTING AT METASTATIC DIAGNOSIS IS CRUCIAL TO HELP OPTIMIZE TREATMENT OUTCOMES<sup>3</sup>

Biomarker testing can help reveal precision medicine options for patients with **BRCA+** mCRPC, who can develop resistance to the current standard of care more quickly than non-**BRCA+** patients.<sup>2,7-9</sup>



Approximately **10%** of men with mCRPC have a **BRCA1** or **2** mutation<sup>10,11</sup>



Approximately **38%** of mCRPC patients are tested for **HRR** mutations, including **BRCA1/2**<sup>5</sup>

The **NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)** recommend both somatic and germline testing for **HRR** mutations, including **BRCA1/2**, in all patients with metastatic prostate cancer.<sup>12</sup>

HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; NCCN, National Comprehensive Cancer Network® (NCCN®).



## UNCOVER **BRCA** IN PROSTATE CANCER

Learn more about the importance of early testing at [UncoverBRCA.com](https://UncoverBRCA.com)

### REFERENCES:

1. Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. *J Hematol Oncol*. 2021;14(1):51.
2. Scott RJ, Mehta A, Macedo GS, et al. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. *Oncotarget*. 2021;12(16):1600-1614.
3. Giri VN, Morgan TM, Morris DS, et al. Genetic testing in prostate cancer management: considerations informing primary care. *CA Cancer J Clin*. 2022;0:1-12.
4. Messina C, Cattrini C, Soldato D, et al. BRCA mutations in prostate cancer: prognostic and predictive implications. *J Oncol*. 2020;4986365.
5. Leith A, Ribbands A, Kim J, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. *Future Oncol*. 2022;18(8):937-951.
6. Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. *J Clin Oncol*. 2019;37(6):490-503.
7. Shore N, Ionescu-Iltu R, Yang L, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. *Future Oncol*. 2021;17(22):2907-2921.
8. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2018;19(7):975-986.
9. Annala M, Struss WJ, Warner EW, et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer. *Eur Urol*. 2017;72(1):34-42.
10. Shore N, Oliver L, Shui I, et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. *J Urol*. 2021;205:977-986.
11. George DJ, Khilfeh I, Rossi C, et al. Real-world prevalence of select homologous recombination repair (HRR) alterations in patients with metastatic castration-resistant prostate cancer (mCRPC). Poster presented at: the 23rd Annual Meeting of the Society of Urologic Oncology; November 30-December 2, 2022; San Diego, CA.
12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 20, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.